Evasion of Immune Responses to Introduced Human Acid α-Glucosidase by Liver-Restricted Expression in Glycogen Storage Disease Type II

This publication has 46 references indexed in Scilit:

• Enumerating Antigen-Specific T-Cell Responses in Peripheral Blood
  Journal of Immunotherapy, 2005
• 867. Correction of Glycogen Storage Disease Type II by Intramuscular Administration of an Adeno-Associated Virus 6 (AAV2/6) Vector Containing a Muscle-Specific Promoter
  Molecular Therapy, 2004
• Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype
  Blood, 2004
• Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII
  Blood, 2003
• Packaging of an AAV vector encoding human acid α-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector
  Molecular Therapy, 2003
• Muscle-Specific Promoters May Be Necessary for Adeno-Associated Virus-Mediated Gene Transfer in the Treatment of Muscular Dystrophies
  Human Gene Therapy, 2001
• Correction of Glycogen Storage Disease Type II by Enzyme Replacement with a Recombinant Human Acid Maltase Produced by Over-Expression in a CHO-DHFRneg Cell Line
  Biochemical and Biophysical Research Communications, 2000
• Enhanced Expression of Transgenes from Adeno-Associated Virus Vectors with the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element: Implications for Gene Therapy
  Human Gene Therapy, 1999
• Quantitation of a urinary tetrasaccharide by gas chromatography and mass spectrometry
  Journal of Mass Spectrometry, 1976
• Increased Excretion of a Glucose‐Containing Tetrasaccharide in the Urine of a Patient with Glycogen Storage Disease Type II (Pompe's Disease)
  European Journal of Clinical Investigation, 1974